Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol

Canadian Journal of Urology

Volumn 20, Issue 1, 2013, Pages 6620-6624

  Pepe, Pietro ^a   Aragona, Francesco ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

Case finding protocol; PCA3; PCPT risk calculator; Prostate cancer; PSA free total; Saturation prostate biopsy

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

AGED; ARTICLE; BIOPSY; BLOOD; CANCER GRADING; DIGITAL RECTAL EXAMINATION; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; URINE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RNA, MESSENGER;

EID: 84884757058     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Pepe P, Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res 2011;31(12):4445-4449.
2. Schroder F, Kattan MW. The comparibility of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008;54(2):274-280.
3. Ankerst DP, Koniarski T, Liang Y et al. Updating risk prediction tools: A case study in prostate cancer. Biom J 2012;54(1):127-132.
4. Hernandez DJ, Han M, Humphreys EB et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int 2009;103(5):609-614.
5. Perdonà S, Cavadas V, Di Lorenzo G et al. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to head comparison of the update PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 2011;59(1):81-87.
6. Nam RK, Kattan MW, Chin JL et al. Prospective multiinstitutional study evaluating the performance of prostate cancer risk calculator. J Clin Oncol 2011;29(22):2959-2964.
7. Oliveira M, Marques V, Carvalho AP, Santos A. Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction. BJU Int 2011;107(11):1780-1783.
8. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, Silva-Ramos M. Prostate cancer prevention trial and European randomized of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol 2010;58(4):551-558.
9. Pepe P, Aragona F. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14453 patients. Prostate Cancer Prostatic Dis 2010;13(4):316-319.
10. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007;70(6):1131-1135.
11. Groskopf J, Aubin SM, Deras IL et al. APTIMA molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52(6):1089-1095.
12. Ankerst DP, Groskopf J, Day JR, Blase A et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 2008;180(4):1303-1308.
13. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction model. Med Decis Making 2006;26(6):565-574.
14. Steyerberg EW, Vickers AJ. Decision curve analysis: a discussion. Med Decis Making 2008;28(1):146-149.
15. Kaplan DJ, Boorjian SA, Ruth K et al. Evaluation of the Prostate Cancer Prevention Trial Risk Calculator in a High-Risk Screening Population. BJU Int 2010;105(3):334-337.
16. Hoffman R, Clanon D, Littenberg B, Frank JJ, Peirce JC. Using free-to-total PSA ratio to detect prostate cancer in men with non specific elevations of PSA levels. J Gen Intern Med 2000;15(10):739-748.
17. Haese A, de la Taille A, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54(5):1081-1088.
18. Ankerst DP, Boeck A, Freedland SJ et al. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the prostate biopsy collaborative group. World J Urol 2012;30(2):181-187.
19. Truong M, Yang B, Jarrard D. Towards the detection of prostate cancer in urine: a critical analysis. J Urol 2013;189(2):422-429. Epub ahead of print.
20. Pepe P, Fraggetta F, Galia A, Skonieczny G, Aragona F. PCA3 score and prostate cancer at repeat saturation biopsy: which cut-off: 20 or 35? Int Braz J Urol 2012;38(4):489-495.
21. Crawford ED, Rove KO, Trabulsi EJ et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012;188(5):1726-1731.
22. Goode RR, Marshall SJ, Duff M, Chevli E, Chevli KK. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013;73(1):48-53. Epub ahead of print.